Pancreatic Cancer Research

ResearcherUniversity of HelsinkiActive in the last 2 years

Toni T. Seppälä

Matched on ORCID iD 0000-0002-4940-3498; OpenAlex author ID A5024265800. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. Patient-derived Organoid Pharmacotyping as a Predictive Tool for Therapeutic Selection in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006517↗
  2. Therapeutic Targeting of Oncogene-Induced Transcription-Replication Conflicts in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2025.02.038↗
  3. In vivo CRISPR screening identifies geranylgeranyl diphosphate as a pancreatic cancer tumor growth dependency. Co-author DOI 10.1016/j.molmet.2024.101964↗
  4. Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Du… Co-author DOI 10.1158/0008-5472.can-23-1660↗
  5. Hereditary colorectal, gastric, and pancreatic cancer: comprehensive review. Co-author DOI 10.1093/bjsopen/zrad023↗
  6. Inflammatory Signaling in Pancreatic Cancer Transfers Between a Single-cell RNA Sequencing Atlas and Co-Culture Co-author DOI 10.1101/2022.07.14.500096↗
  7. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-21-4165↗
  8. Can Pancreatic Organoids Help in the Treatment of Pancreatic Cancer? Co-author DOI 10.1016/j.yasu.2021.05.015↗
  9. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004200↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Richard Andrew Burkhart · 6 shared papers, 2020–2024 · strength 1.01
  2. Richard A. Burkhart · 3 shared papers, 2023–2026 · strength 0.75
  3. Jin Peng He · 5 shared papers, 2020–2026 · strength 0.69
  4. Elizabeth M. Jaffee · 5 shared papers, 2020–2026 · strength 0.69
  5. Jacquelyn W. Zimmerman · 5 shared papers, 2020–2026 · strength 0.69
  6. Elana Judith Fertig · 3 shared papers, 2022–2026 · strength 0.49
  7. Samantha R. Guinn · 3 shared papers, 2022–2026 · strength 0.49
  8. David Tsai Ting · 4 shared papers, 2020–2024 · strength 0.45
  9. Reecha Suri · 4 shared papers, 2020–2024 · strength 0.45
  10. David P. Ryan · 4 shared papers, 2020–2024 · strength 0.45
  11. Christopher L. Wolfgang · 3 shared papers, 2022–2024 · strength 0.36
  12. Alec C. Kimmelman · 3 shared papers, 2022–2024 · strength 0.36
  13. Lei Zheng · 3 shared papers, 2022–2024 · strength 0.36
  14. Christopher R. Shubert · 2 shared papers, 2022–2026 · strength 0.36
  15. Kelly J. Lafaro · 2 shared papers, 2022–2026 · strength 0.36
  16. Bryson W. Katona · 1 shared paper, 2023 · strength 0.31
  17. Peter J. Espenshade · 1 shared paper, 2024 · strength 0.28
  18. Casie S. Kubota · 1 shared paper, 2024 · strength 0.28
  19. Dimitrios N. Sidiropoulos · 2 shared papers, 2022–2024 · strength 0.25
  20. Jacob T. Mitchell · 2 shared papers, 2022–2024 · strength 0.25
  21. Luciane Tsukamoto Kagohara · 2 shared papers, 2022–2024 · strength 0.25
  22. Jun Yu · 2 shared papers, 2022–2024 · strength 0.25
  23. Benedict Kinny‐Köster · 2 shared papers, 2022–2024 · strength 0.25
  24. Laura DeLong Wood · 2 shared papers, 2022–2024 · strength 0.25
  25. William Reece Burns · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.